Insights On Upstream Manufacturing

  1. Top 5 Cell Line Development Challenges (And How To Avoid Them) 11/6/2025

    The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

  2. Optimize Your CLD With Innovative And Flexible Transposase Technology 11/6/2025

    To ensure speed and stability in the manufacture of your complex biologic — mAbs, antibodies, fusion proteins, and/or antibody drug conjugates — prioritize a high-performance CLD workflow.

  3. Achieve Speed, Stability, And Compliance In Cell Line Development 11/6/2025

    Partnering with a CDMO that demonstrates innovative and commercially validated cell line development capabilities is essential to protecting your market position and securing investor support.

  4. Unlocking ROI And Capacity In Monoclonal Antibody Manufacturing 11/5/2025

    Perfusion-based upstream production offers up to 24% lower cost and significantly higher productivity than fed-batch, enabling faster timelines, better facility utilization, and improved quality.

  5. Dry Powder Media Manufacturing Grand Island Expansion 11/5/2025

    Take a video tour of our newly expanded dry powder media manufacturing facility in Grand Island, New York. The expansion has added more than 45,000 square feet of Animal Origin Free (AOF) manufacturing space to help meet increasing global demand.

  6. What Are MSCs And How Are They Used? 11/4/2025

    Learn about the defining criteria and varied tissue sources of MSCs. Discover their expanding role in therapies targeting inflammatory conditions and tissue regeneration.

  7. Streamline Your Workflow With An Innovative Fixed-Bed System 11/4/2025

    Discover how an innovative fixed-bed system streamlines workflows and supports consistent, high-yield manufacturing across a range of applications.

  8. Scale Your Viral Vector Production With A Streamlined Bioreactor System 11/4/2025

    Scale your viral vector or vaccine production with a streamlined, intermediate-scale bioreactor system that bridges development and commercial manufacturing, supporting applications from exosomes to vaccines.

  9. Accelerating Process Scale-Up From Benchtop To Commercialization- From Controller To Software 11/4/2025

    Discover strategies for optimizing process control, refining media selection, and ensuring safety through rigorous contaminant detection to mitigate development risks.

  10. Multi-Omics In Cell Culture Media Design 11/4/2025

    Discussing the evolution of medium design for cell culture bioprocessing, and the role that multi-omics and bioinformatics can play in improved medium development.